Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic

NCT00977522 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00977522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00977522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2009
Completion date
September 30, 2010
Enrollment
207 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia